

Figure 1 - figure supplement 1

Patient ID	Clonal family	mAb name	VH			VL			Crude [IgG] (µg/mL)	Fold change in binding		% Neutralization					
			Gene	% nt mutation	CDR3 aa length	Gene	% nt mutation	CDR3 aa length		DENV2 rE	DENV2 RVP	DENV1	DENV2	DENV3	DENV4	ZIKV	WNV
020	1	B10	4-39	2.68	10	1-9	2.47	9	3.21	6	12	65	43	64	69	38	11
013		M1	4-39	10.77	10	1-9	1.06	9		4	13	73	77	65	84	33	47
020		D8	4-39	5.30	10	1-9	2.13	9	1.77	2	15	48	41	55	42	28	44
013	2	M6	1-69	2.72	15	1-40	4.73	11		2	1	-6	10	36	53	27	36
013		H3	1-69	5.44	15	1-5	3.48	10	1.26	34	7	41	72	64	84	0	47
013	3	P4(405)	1-18	7.53	16	2-14	1.68	10	<0.0005	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
013		I13	1-18	7.53	16	2-14	3.37	10	<0.0005	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
020	4	I7	1-3	5.42	16	1-39	7.04	9	1.65	34	14	41	67	57	49	13	76
013	5	C4	1-69	10.17	17	1-5	2.12	8	2.47	1	1	96	74	96	65	22	46
013		J2	1-69	10.51	17	1-5	2.47	8	<0.0005	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
013		N2	1-69	8.81	17	1-5	2.12	8	1.97	1	1	98	-10	65	69	3	39
020	6	L8	1-69	4.07	13	1-40	0.67	12	3.93	9	7	68	81	78	92	28	45
020		H1	1-69	4.41	13	1-40	0.67	12	<0.0005	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
013	7	J8	1-69	9.86	16	3-11	1.39	12	<0.0005	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
013		J9	1-69	10.44	16	3-11	3.83	12	4.04	1	5	100	100	100	100	20	29
013	8	J3	1-69	9.22	17	2-14	7.22	12	0.95	1	2	97	59	74	40	6	30
013		P4(403)	1-69	7.51	17	2-14	3.48	12	2.35	1	1	100	44	78	43	5	25
013	9	M11	1-69	8.45	20	3-15	3.48	9	4.04	1	2	100	39	59	56	25	49
013		M4	1-69	6.76	20	3-15	2.44	9	2.54	1	1	100	1	39	40	5	33
013		L3	1-69	5.07	20	3-15	2.44	9	2.40	1	2	100	18	53	53	22	45
013		K11	1-69	6.08	20	3-15	2.79	9	3.97	1	1	100	-17	47	44	14	33
013		O4	1-69	7.43	20	3-15	2.44	9	1.74	1	1	100	0	40	58	5	34
013	10	I11	3-30-3	3.08	14	3-15	1.77	8	1.61	2	3	84	10	31	57	14	22
013		C1	3-30-3	4.11	14	3-15	3.92	8		n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
013		G5	3-30-3	4.80	14	3-15	1.43	8	nc	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
013		P2	3-30-3	5.14	14	3-15	3.90	8	4.13	1	1	96	16	34	49	7	28
013		A7	3-30-3	10.27	14	3-15	4.26	8	2.16	1	2	97	30	20	55	14	32
013		L9	3-30-3	5.78	14	3-15	4.26	8	1.92	39	2	-16	0	52	78	19	35
013		E9	3-30-3	8.11	23	1-40	3.43	10	<0.0005	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
013	11	I8	3-30-3	8.78	23	1-40	4.45	10	nc	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
020	12	E1	3-7	2.71	17	8-61	2.03	10		n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
020		F10	3-7	4.41	17	8-61	2.70	10	3.96	2	3	-28	-8	40	63	6	15
013	13	N8	4-34	7.85	18	2-14	6.49	12	2.55	1	1	99	0	34	61	4	11
013		F4	4-34	5.12	18	2-14	3.05	12	1.41	1	1	100	1	48	58	6	20
020	14	K2	4-39	2.34	15	1-5	1.76	8	2.09	1	1	-32	24	44	54	26	39
020		A5	4-39	1.67	15	1-5	1.41	8	3.63	1	1	-5	23	53	75	20	37
013	15	P10	4-59	6.21	23	1-39	2.11	8	0.72	1	11	25	68	66	74	27	20
013		L2	4-59	7.29	23	1-39	6.43	8	4.66	1	14	10	61	60	61	25	9
3H5-1	DENV2-specific mAb		n/a	n/a	n/a	n/a	n/a	n/a	n/a	44	10	nd	nd	nd	nd	nd	nd
EDE2 B7	DENV cross-reactive mAb		3-74	6.94	26	2-23	4.51	10	n/a	1	3	nd	nd	nd	nd	nd	nd
EDE1 C10	DENV/ZIKV cross-reactive mAb		1-3	2.78	21	2-14	3.82	10	n/a	nd	nd	100	99	92	100	99	-99
CR4354	WNV-specific mAb		n/a	n/a	n/a	n/a	n/a	n/a	n/a	nd	nd	-127	-57	-149	-139	-48	93

Fold change in binding	% Neutralization
≥11	90-100
5-10	75-89
2-4	51-74
1	≤50